Equity Profile
Pre-Earnings Brief
Immunome Inc (IMNM) is a biotechnology company focused on developing therapies for cancer and infectious diseases using its proprietary antibody discovery platform. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments continues to grow.
EPS
Earnings per share will provide insight into the company's financial health and operational efficiency this quarter.
Revenue
While revenue estimates are not available, any reported figures will be crucial for understanding market demand for Immunome's products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
25%
Avg EPS Surprise
-70.59%
Avg Stock Reaction
-2.13%
In the last quarter, Immunome reported a significant earnings miss, with an EPS of -$2.43 compared to an estimate of -$0.65. This disappointing performance led to a decline in stock price the following day.
Management Promises & Guidance
Overall expectations for Immunome's upcoming earnings are mixed, with uncertainty surrounding its ability to meet or exceed previous performance metrics. The lack of analyst estimates adds to the unpredictability.
Bull Case
If Immunome can demonstrate progress in its clinical trials or unveil new partnerships, it could significantly boost investor confidence and drive the stock price higher.
Bear Case
Conversely, if the company continues to report losses and fails to provide clear guidance on its future prospects, it could lead to further declines in stock value.
EPS
N/AEarnings per share will provide insight into the company's financial health and operational efficiency this quarter.
Revenue
N/AWhile revenue estimates are not available, any reported figures will be crucial for understanding market demand for Immunome's products.
Expectations
The print will turn on these two things.
Q1
What will be the reported EPS this quarter?
Given the company's recent history of earnings misses, the EPS figure will be critical in assessing whether Immunome is making progress in its financial recovery.
Q2
What updates will be provided on ongoing clinical trials?
Updates on clinical trials can significantly influence investor sentiment and stock performance, as they reflect the company's potential for future revenue.
Edge
Why consensus could be wrong
The Street may underestimate the potential impact of positive clinical trial results, which could significantly alter perceptions of Immunome's future.
Supporting Evidence
The company's recent focus on innovative therapies could yield unexpected positive results.
Options pricing suggests a higher expected move than historical averages, indicating that traders are preparing for significant news.
Key Risk
If clinical trial updates show promising results, it could shift the narrative and lead to a positive reassessment of the company's prospects.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is crucial for Immunome as it seeks to regain investor confidence after a series of disappointing earnings.
Bull Confirmed If
A reported EPS better than -$2.00 would confirm a positive turnaround in financial performance.
Bear Confirmed If
An EPS worse than -$2.50 would reinforce concerns about the company's financial stability.
Pre-Earnings Positioning
Implied Move
±5%
Historical Avg
±4.0%
The options market is pricing in a 5% move, indicating that traders expect some volatility around the earnings report.
Options are pricing ±5.0% while IMNM has averaged ±4.0% over the last 8 prints — setup is pricing rich.
30d HV
54.6%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Immunome beats expectations, history suggests a potential stock increase of around +1.42%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.
Miss
A miss could lead to a decline of approximately -3.42%, reflecting ongoing concerns about the company's financial health.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CREDIT ACCEP CORP MI